1. Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2023
2. Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a);Neurology, Neuropsychiatry, Psychosomatics;2022-08-04
3. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related MicroRNAs in Multiple Sclerosis;Iranian Journal of Allergy, Asthma and Immunology;2022-06-21
4. New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»);Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2022
5. Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2022